Moncef Slaoui

Moncef Slaoui General Information

Description

Dr. Moncef Slaou serves as Board Member at Monopteros Therapeutics. He is an Angel Investor. He served as a Partner & Member of the Scientific Advisory Board at Medicxi. He served as Chief Scientific Officer & Advisor at Centessa Pharmaceuticals. He also is an Angel Investor. He formerly served as President, Chairman & Head of Research and Development of the Vaccines Division at GSK. He has extensive clinical, medical, scientific, and leadership experience, gained during his 28 years at GSK, with the Medicxi team. In his role as head of R&D at GSK between 2006 and 2014, Dr. Slaoui was the architect of a pioneering re-organization of the Company's R&D effort, operating through focused discreet discovery performance units (DPUs) in the early stage, which competed internally for R&D investment, a unique model amongst Big Pharma at the time. As a member of the Scientific Advisory Boards of both the IL6 and MV1 venture funds, Dr. Slaoui has been closely involved with Medicxi (and previously Index Ventures) for many years. As a Partner, he is responsible for sponsoring and supporting investments, undertaking due diligence and valuations for Medicxi's venture fund MV1 and its growth fund MG1. He is Chairman of the board at Galvani Bioelectronics, and also serves on the boards of Artisan Biosciences, and Moderna Therapeutics. He earned a Ph.D. in Molecular Biology and Immunology from the Université Libre de Bruxelles, Belgium, and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston. He was a Professor of Immunology at the University of Mons, Belgium. He also serves as a Chairman at SutroVax.